Annovis Bio, Inc. (ANVS)
- GlobeNewswire
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase II/III data from its Alzheimer’s study and sharing next steps. Dear Friends, The last few days have been very difficult. I received a lot of emails and phone ca
- Zacks
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
- Zacks
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.
